KCT0008425终止Unknown
A Phase 1, Single-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered JBPOS0501 in Healthy Volunteers
Bio-Pharm Solutions0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 终止
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •1. Males or females, of any race, between 19 and 55 years of age, inclusive.
- •2. BMI between 19.0 and 32.0 kg/m2, inclusive, with a minimum weight of at least 50.0 kg at the time of screening and on Day -1 (admission date).
- •3. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert’s syndrome based on total and direct bilirubin] is not acceptable) at screening and on the date of admission as assessed by the investigator (or designee).
- •4. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Appendix 4.
- •5. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
排除标准
- •1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
- •2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
- •3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.(uncomplicated appendectomy and hernia repair will be allowed).
- •4. Males with QTcF >430 ms and females with QTcF >450 ms on 12-lead ECG performed at screening prior to drug administration (The average result is used by repeating three ECG measurements.)
- •5. Any of the following:
- •a. QTcF >430 ms (male), QTcF >450 ms (Female) confirmed by calculating the mean of the original value and 2 repeats.
- •b. QRS duration >120 ms confirmed by calculating the mean of the original value and 2 repeats.
- •c. PR interval >220 ms confirmed by calculating the mean of the original value and 2 repeats.
- •d. findings which would make QTc measurements difficult or QTc data uninterpretable.
- •e. history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
- •6. Confirmed systolic blood pressure >150 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, and pulse rate >100 or <40 beats per minute.
- •7. History of alcoholism or drug/chemical abuse within 2 years prior to screening visit.
- •8. Alcohol consumption of >21 units/week for males and >14 units/week for females. (One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL)
- •9. Positive urine drug screen at screening or positive alcohol breath test result or positive urine drug screen at screening.
- •10. Positive hepatitis panel and/or positive rapid plasma reagin test and/or positive human immunodeficiency virus test (Appendix 2).
- •11. Participation in a clinical study involving administration of an investigational drug, in the past 6 months or 5 half-lives, whichever is longer prior to dosing.
- •12. Administration of an approved (authorized) Coronavirus Disease 2019 (COVID-19) vaccine in the past 30 days prior to dosing.
- •13. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John’s wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
- •14. Use of any medication known to be inhibitors or inducers of CYP1A2, CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 activity within 30 days prior to dosing until the follow up visit.
- •15. Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the investigator (or designee).
- •16. Use or intend to use medications/products considered to still be active within 14 days prior to dosing, unless deemed acceptable by the investigator (or designee).
- •17. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to date of admission, unless deemed acceptable by the investigator (or designee).
研究者
相似试验
招募中
不适用
A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study to Evaluate the Safety and Tolerability of SKL20540 in Healthy SubjectsMental and behavioral disordersKCT0002938SK Biopharmaceuticals92
进行中（未招募）
1 期
A Pneumococcal Vaccine Study A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorHealthy volunteers (toddlers), Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorMedDRA version: 20.0Level: LLTClassification code 10078416Term: Invasive bacterial infectionSystem Organ Class: 100000004862EUCTR2019-004503-12-Outside-EU/EEAAstellas Pharma Global Development Inc.
已完成
不适用
A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusioTraumatic brain injuryInjury, Occupational Diseases, PoisoningISRCTN67656669euren Pharmaceuticals (New Zealand)35
已完成
不适用
A Phase I, single*center, double-blind, randomized, placebo-controlled, single and multiple ascending dose trial to evaluate the safety and pharmacokinetics of PTC857 in healthy volunteers.10007951Parkinson's DiseaseNL-OMON49571PTC Therapeutics, Inc.82
招募中
1 期
This is a randomized, double-blind, two-arm, single-dose, parallel-group study in normal healthy adult male volunteers.CTRI/2024/02/063265Biocon Biologics UK Limited